RWA
TEVA icon

Redhawk Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Redhawk Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,416
Closed -$1.16M – 326
2024
Q4 		$1.16M Buy
+52,416
New +$954K 0.16% 112

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Redhawk Wealth Advisors's TEVA Position: Q1 2025 in Review

Redhawk Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 52,416 shares — an estimated $1.16M sold.

Redhawk Wealth Advisors first reported a position in TEVA in Q4 2024 and held it in 1 quarter. The position peaked at $1.16M in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Redhawk Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Redhawk Wealth Advisors sold 52,416 Teva Pharmaceuticals shares in Q1 2025, an estimated $1.16M.
  • Redhawk Wealth Advisors first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Redhawk Wealth Advisors's Teva Pharmaceuticals position peaked at $1.16M in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Redhawk Wealth Advisors's 13F filing for Q1 2025, filed 15 Apr 2025.